株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

若年性黄斑変性症(シュタルガルト病):パイプライン製品の分析

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 257806
出版日 ページ情報 英文 69 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.35円で換算しております。
Back to Top
若年性黄斑変性症(シュタルガルト病):パイプライン製品の分析 Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2017
出版日: 2017年03月31日 ページ情報: 英文 69 Pages
概要

若年性黄斑変性症は児童期・少年期に発症する遺伝性の眼病で、その最も一般的な形態はシュタルガルト病と呼ばれています。シュタルガルト病は先天性の常染色体劣性遺伝の症候群です。主な症状・徴候として、視野がぼやけたり、視野の中心部に暗点が現れたりして、読書や細かい作業ができなくなることが挙げられます。主なリスク要因には、動脈硬化症や高コレステロール血症、喫煙、高血圧などがあります。

当レポートでは、世界各国での若年性黄斑変性症(シュタルガルト病)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

若年性黄斑変性症の概要

治療薬の開発

  • 若年性黄斑変性症向けパイプライン製品:概要
  • 企業で開発されたパイプライン
  • 大学/研究機関で開発されたパイプライン
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Acucela Inc.
  • Alkeus Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Copernicus Therapeutics Inc
  • Grupo Ferrer Internacional SA
  • Iris Pharma
  • Sanofi

薬剤プロファイル

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9106IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Juvenile Macular Degeneration - Pipeline Review, H1 2017, provides an overview of the Juvenile Macular Degeneration (Ophthalmology) pipeline landscape.

Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease. Stargardt's disease is an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision, dark, empty spots in the center of vision and difficulty reading or performing detail work. Risk factors include arteriosclerosis, hypercholesterolemia, smoking and hypertension.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Juvenile Macular Degeneration - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Juvenile Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 5 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Juvenile Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Juvenile Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Juvenile Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Juvenile Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Juvenile Macular Degeneration (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Juvenile Macular Degeneration (Stargardt Disease) - Overview
    • Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Juvenile Macular Degeneration (Stargardt Disease) - Companies Involved in Therapeutics Development
    • Acucela Inc
    • Alkeus Pharmaceuticals Inc
    • Astellas Pharma Inc
    • Copernicus Therapeutics Inc
    • Grupo Ferrer Internacional SA
    • Iris Pharma
    • Sanofi
  • Juvenile Macular Degeneration (Stargardt Disease) - Drug Profiles
    • ALK-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • echothiophate iodide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emixustat hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FAB-111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy 1 to Activate ABCA4 for Stargardt Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBS-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MA09-hRPE - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides to Activate ABCA4 for Stargardt Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ramiprilat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-422459 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • soraprazan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Ophthalmic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects
  • Juvenile Macular Degeneration (Stargardt Disease) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 26, 2017: Acucela Initiates Phase 2a Study of Emixustat Hydrochloride Addressing Patients with Stargardt Disease
      • Jan 05, 2017: Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease
      • May 26, 2015: Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases
      • May 04, 2015: European Medicines Agency Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease
      • Mar 31, 2015: Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies
      • Oct 15, 2014: ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration
      • Sep 25, 2014: Advanced Cell Technology Announces Final Patient Treated in Stargardt's Macular Degeneration Phase 1 Trial in the United Kingdom
      • Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials
      • Jun 03, 2013: Oxford BioMedica Halts Recruitment Into Phase I/IIa Study Of StarGen
      • May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells
      • Apr 23, 2013: ACT Initiates Higher-Dosage Patient Treatment In European Phase I Study For Macular Degeneration
      • Apr 15, 2013: ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt's Macular Dystrophy
      • Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy
      • Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells
      • Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Acucela Inc, H1 2017
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alkeus Pharmaceuticals Inc, H1 2017
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Astellas Pharma Inc, H1 2017
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Copernicus Therapeutics Inc, H1 2017
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Grupo Ferrer Internacional SA, H1 2017
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Iris Pharma, H1 2017
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Sanofi, H1 2017
  • Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top